ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500™
BAUDETTE, Minn., /PRNewswire/ -- ANI Pharmaceuticals, Inc., ("ANI") (NASDAQ: ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. ANI revenue grew 216% during this period.
ANI's President and CEO, Arthur S. Przybyl, said, "I want to thank our employees for their hard work and contributions, which have enabled ANI to be listed on Deloitte's Technology Fast 500™ for the second year in a row. Through a mixture of acquisitive and organic growth, ANI's revenue grew by 216% from 2014 to 2017, and we're proud to be listed on Deloitte's Technology Fast 500™ again in 2018."
"Congratulations to the Deloitte 2018 Technology Fast 500 winners on this impressive achievement," said Sandra Shirai, vice chairman, Deloitte LLP, and U.S. technology, media and telecommunications leader. "These companies are innovators who have converted their disruptive ideas into products, services and experiences that can captivate new customers and drive remarkable growth."
"Software, which accounts for nearly two of every three companies on the list, continues to produce some of the most exciting technologies of the 21st century, including innovations in artificial intelligence, predictive analytics and robotics," said Mohana Dissanayake, partner, Deloitte & Touche LLP, and Industry Leader for technology, media and telecommunications, within Deloitte's audit and assurance practice. "This year's ranking demonstrates what is likely a national phenomenon, where many companies from all parts of America are transforming the way we do business by combining breakthrough research and development, entrepreneurship and rapid growth."
ANI Pharmaceuticals, Inc. previously ranked at 279 as a Technology Fast 500™ award winner for 2017.
Overall, 2018 Technology Fast 500™ companies achieved revenue growth ranging from 143 percent to 77,260 percent from 2014 to 2017, with median growth of 412 percent.
About Deloitte's 2018 Technology Fast 500™
Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2014 to 2017.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.
For more information about ANI, please contact:
SOURCE ANI Pharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:ANIP